Abstract

Clinical Applications of Circulating Tumor Cells to Predictive Oncology

Patrizia Paterlini-Brechot, Professor of Oncology/Molecular Biology, University Paris Descartes

Circulating Tumor Cells (CTC) and Circulating Tumor Microemboli (CTM) are Circulating Rare Cells which herald tumor invasion and are expected to provide an opportunity to improve the management of cancer patients and help to detect the most aggressive invasive cancers before other diagnostic approaches like imaging. We report on the clinical applications of CTC in predictive oncology and more specifically on the ISET® (Isolation by SizE of Tumor/Trophoblastic Cells) open system for marker-independent isolation of tumor cells from blood which allows to reliably diagnose and count CTC.

Independent published data from several international research teams have demonstrated the prognostic relevance of CTC detection by ISET® in patients with melanomas, as well as lung, colorectal, liver,  pancreatic, head and neck, and ovarian cancers. Furthermore, the utility of theranostic characterization of CTC by ISET® has been demonstrated for non-small-cell lung cancers, colorectal cancers and melanomas.